24 April 2018 |

EryDel raises €26,5 Million in financing

Innogest participates in the round led by Sofinnova Partners. Funds will be used to accelerate the company’s international development and complete the registrational Phase III clinical trial of its lead product EryDex

16 June 2017 |

Bone regeneration, GreenBone raises a €8,4M investment round

GreenBone Ortho, a Faenza (Italy) based company that provides innovative, easy to use bio-inspired solutions designed to help cure severe bone diseases, has raised an investment round led by Helsinn Investment Fund, Invitalia Ventures and Innogest to further develop its revolutionary wood-derived, bone regenerative implant for extensive bone damage

01 December 2017 |

Innogest lancia Italian Patents Competition, 250.000 euro in palio per brevetti nelle lifescience e nel digital

TORINO-MILANO, 1 DICEMBRE 2017 – Innogest, in collaborazione con Deloitte e con la Direzione Generale per la lotta alla contraffazione–Ufficio Italiano Brevetti e Marchi del Ministero dello sviluppo economico, ha presentato oggi la prima edizione della Italian Patents Competition. Il bando – pubblicato all’indirizzo www.innogestcapital.com/patents-competition – si rivolge a progetti basati su brevetti sviluppati in Italia

20 March 2017 |

Innogest invests in MedLumics, €34m Series B Round closed

MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, announced today the largest round in the history of medtech in Spain and one of the largest in Europe this year. Led by Edmond de Rothschild Investment Partners (EdRIP), the Series B round included funding from new investors Seroba Life Sciences, Innogest Capital, as well as from existing investors Ysios Capital Partners and Caixa Capital Risc

20 March 2017 |

Partnership tra ZCube e Innogest per il programma Open Accelerator

Innogest collabora con ZCube, research venture del gruppo farmaceutico Zambon, per la ricerca e lo sviluppo di startup innovative nel campo delle life science, nell'ambito del programma Open Accelerator. Nuova call for ideas in apertura il 3 aprile prossimo

06 March 2017 |

EryDel announces start of ATTEST, Pivotal Phase III Trial in Ataxia Telangiectasia

EryDel SpA, a biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study, a pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of EDS in patients with A-T